Kamada KMDA
NASDAQ KMDA
$8.21 -0.08 (-0.97%)
As of: Sep 9, 2026 · 3:59 PM EDT

Kamada (KMDA) Receivables (2012 - 2026)

Kamada's (KMDA) quarterly Receivables came in at $44.0 million in Q2 2026, up 14.9% on a YoY basis from $38.3 million in Q2 2025, and little changed quarter-over-quarter from $43.9 million in Q1 2026.

Analysis

Kamada (KMDA) Receivables (2012 - 2026) Analysis & Trends

Kamada (KMDA) has reported Receivables for 15 consecutive years, with $44.0 million the latest figure, recorded in Q2 2026.

  • For the quarter ending Q2 2026, Receivables rose 14.9% year-over-year to $44.0 million; the trailing twelve-month figure through Jun 2026 stood at $44.0 million (up 14.9% YoY), and the FY2025 full-year result was $34.6 million, up 16.86% from the prior year.
  • Receivables was little changed at $44.0 million in Q2 2026 per KMDA's latest filing, from $43.9 million in the prior quarter.
  • Across five years, Receivables topped out at $44.0 million in Q2 2026 and bottomed at $20.0 million in Q4 2023.
  • Historically, Receivables has averaged $32.0 million across 5 years, with a median of $33.3 million in 2023.
  • The sharpest annual moves came in 2023 and 2025: Receivables tumbled 42.55% in 2023, then surged 59.76% in 2025.
  • Over 5 years, Receivables stood at $34.8 million in 2022, then sank by 42.55% to $20.0 million in 2023, then gained by 9.01% to $21.8 million in 2024, then jumped by 58.39% to $34.6 million in 2025, then climbed by 27.39% to $44.0 million in 2026.
  • According to Business Quant data, Receivables over the past three periods registered $44.0 million, $43.9 million, and $34.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Receivables (Qtr)
1 Amgen 211.73 Bn 197.74 Bn 7.24 Bn 10.23 Bn
2 Gilead Sciences 180.92 Bn 177.74 Bn 6.22 Bn 5.90 Bn
3 Vertex Pharmaceuticals 132.16 Bn 124.30 Bn 2.84 Bn 2.13 Bn
4 Regeneron Pharmaceuticals 82.89 Bn 74.90 Bn 3.93 Bn 6.57 Bn
5 Argenx Se 61.41 Bn 56.23 Bn 1.37 Bn 1.93 Bn
6 Moderna 53.99 Bn 48.85 Bn 52.00 Mn 160.00 Mn
7 Alnylam Pharmaceuticals 34.48 Bn 31.18 Bn 992.69 Mn 912.74 Mn
8 Biogen 31.15 Bn 29.86 Bn 1.96 Bn 1.89 Bn
9 Roivant Sciences 30.05 Bn 30.05 Bn 1.16 Mn -
10 Kamada 473.57 Mn 403.43 Mn 22.47 Mn 44.01 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 44.01 Mn
Mar 31, 2026 43.94 Mn
Dec 31, 2025 34.55 Mn
Sep 30, 2025 39.07 Mn
Jun 30, 2025 38.31 Mn
Mar 31, 2025 35.80 Mn
Dec 31, 2024 21.81 Mn
Sep 30, 2024 24.45 Mn
Jun 30, 2024 34.49 Mn
Mar 31, 2024 27.24 Mn
Dec 31, 2023 20.01 Mn
Sep 30, 2023 33.65 Mn
Jun 30, 2023 32.85 Mn
Mar 31, 2023 28.68 Mn
Dec 31, 2022 34.83 Mn
Sep 30, 2022 31.16 Mn
Jun 30, 2022 24.10 Mn
Mar 31, 2022 27.56 Mn
Dec 31, 2021 40.72 Mn
Sep 30, 2021 31.54 Mn